Anthera Pharmaceuticals, Inc.
ANTH · OTC
3/31/2018 | 12/31/2017 | 9/30/2017 | 6/30/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $8 | $6 | $7 |
| G&A Expenses | $4 | $2 | $2 | $2 |
| SG&A Expenses | $4 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $9 | $8 | $9 |
| Operating Income | -$11 | -$9 | -$8 | -$9 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | -$0 | $2 | $9 |
| Pre-Tax Income | -$8 | -$10 | -$6 | $0 |
| Tax Expense | -$3 | $0 | -$2 | -$9 |
| Net Income | -$4 | -$10 | -$5 | $9 |
| % Margin | – | – | – | – |
| EPS | -0.2 | -0.76 | -0.43 | 0.92 |
| % Growth | 73.7% | -76.7% | -146.7% | – |
| EPS Diluted | -0.2 | -0.76 | -0.43 | 0.92 |
| Weighted Avg Shares Out | 22 | 13 | 11 | 10 |
| Weighted Avg Shares Out Dil | 22 | 13 | 11 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$3 | $0 | -$2 | -$9 |
| EBITDA | -$11 | -$9 | -$8 | -$8 |
| % Margin | – | – | – | – |